Proactive investorsLogo Proactive Investors UK Website

Search field
Get Adobe Flash Player Download
Flash
Player ►

And
Enable
Javascript

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals
Epic: EHP
News: Latest news
Web Site: Epistem
Other Articles: 16-03-201009-03-2010 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive UK ▼

Thursday July 29, 09:30Specialist Energy Group Lays Out a Compelling Blueprint for Growth

After a difficult start to life as a stock market listed company, the company now stands at the threshold of a much brighter future. Legacy issues have been dealt with and the turnaround programme initiated by CEO Ewan Lloyd-Baker is gaining traction.

FULL ARTICLE ► 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive AU ▼

Wednesday July 28, 11:30Silver Lake Resources boosts high grade gold resource by 70% to 2.5m ounces

Silver Lake Resources has added over 1 million ounces of gold to its resource inventory during the year after mining 66,700 ounces and expects further encouraging results at its  Mount Monger and Murchison projects.

FULL ARTICLE ► 
Warning (2): curl_setopt() [function.curl-setopt]: CURLOPT_FOLLOWLOCATION cannot be activated when in safe_mode or an open_basedir is set [APP/models/web_model.php, line 120]

RSS - Subscribe to the News Today on Proactive CN ▼

Thursday July 15, 02:10Henan Yuguang Lead & Gold investment in Kimberley Metals receives all clear from FIRB

Kimberley Metals (ASX: KBL) has reported that on 12 July the Australian Government Foreign Investment Review Board (FIRB) had no objections to Henan Yuguang Lead & Gold Co. Ltd's [...]

FULL ARTICLE ►
Epistem

Epistem

Epistem is a biotechnology company applying its expertise in epithelial stem cells in the areas of oncology and gastrointestinal diseases as well as dermatological applications. Epistem has become recognised as a specialist in epithelial tissue and stem cell analyses. Our heritage is based on our expert science and know-how in the field of epithelial tissue and adult epithelial stem cell biology.

CLICK HERE FOR FULL ANLAYSIS OF EPISTEM
Tuesday, March 16, 2010

Edison Investment comments on Epistem interims

Edison Investment Research said that Epistem’s interim results last week show that it is maintaining its position in the competitive contract research and biomarker business. According to Edison, Epistem is profitable and it is supported by the prospect of future royalties and milestones from the Novartis deal, which ends in February 2011.

The research house noted that the company’s major two-year Novartis deal is well underway and it is progressing strongly. Through the Novartis collaboration, Epistem received £2.8m upfront in March 2009, and it is to receive a further £1.2m per year in direct R&D costs. Edison noted that Epistem achieved a 90% increase in revenues relating to the collaboration compared to H109.

As the deal passes its first anniversary, Edison indicated that a renewal of the Novartis collaboration may prove to be influential for Epistem.

Additionally Edison identified Epistem’s Biomarker business as a potential growth area. The researcher noted that the number of new tests used in inflammatory bowel disease may be growing, and a US government contract remains important. According to Edison the division is stable overall with a loyal customer base.

Edison said the Biomarker business remains a major potential growth area for Epistem, with potential sales estimated in the £2-3m range by 2012-13. However the research house also said that whilst it is still too early to tell after 18 months, there is no obvious sales momentum. According to Edison, a major clinical trial contract would transform the business and would subsequently lead to other customers.

Epistem has indicated its desire to acquire a revenue earning, profitable, high-growth diagnostics business although a transforming one-off transaction has proved difficult, Edison said. Alternatively a series of smaller transactions would be more complex to execute and integrate, but may offer better returns, the researcher added.

AddThis Feed Button
Register here to be notified of future Epistem articles.

Other Epistem news

More news ►

Investors interested in Epistem recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.